D-serine for Posttraumatic Stress Disorder Treatment
- Registration Number
- NCT00215878
- Lead Sponsor
- Herzog Hospital
- Brief Summary
The aim of this study is to asses the effects of the NMDA receptor full agonist D-serine while used as adjuvant treatment for individuals suffering from chronic posttraumatic stress disorder (PTSD). Dysfunction of neurotransmission mediated at NMDA receptor plays a cardinal role in the pathophysiology of PTSD and PTSD patients typically suffer from cognitive dysfunctions and avoidance\& depressive symptomatology that may be mediated by NMDA receptor function deficits.
Thus, enhancement of NMDA activity by using D-serine may be beneficial in the treatment of PTSD. The study design involves two 6 week periods during which the participants will be randomly assigned to receive treatment with D-serine (\~2g /dy)and placebo. This design allows each participant the opportunity to respond to the experimental treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
• Chronic PTSD (DSM-IV diagnosis)
- Other psychiatric diagnosis
- Substance abuse
- Unstable medical condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 D-serine (~2g /day) Adjuvant 6 weeks treatment with placebo (\~2g /day) 2 D-serine (~2g /day) Adjuvant 6 weeks treatment with D-serine (\~2g /day)
- Primary Outcome Measures
Name Time Method CAPS scores 6 week treatment
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Ezrat Nashim-Herzog Memorial Hospital
🇮🇱Jerusalem, Israel